Taisho Pharmaceutical Co., Ltd.
๐ฏ๐ตJapan
Safety and Efficacy of SFPP in Knee Osteoarthritis
Phase 3
Completed
- Conditions
- Osteoarthritis Knee Pain
- Interventions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 313
- Registration Number
- NCT03434197
- Locations
- ๐ฎ๐ฉ
Klinik Perisai Husada, Bandung, Indonesia
๐ฎ๐ฉRumah Sakit TNI AU Soemitro, Surabaya, Indonesia
๐ฎ๐ฉRumah Sakit Islam Pd. Kopi, Jakarta, Indonesia
Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #2
Not Applicable
Completed
- Conditions
- Healthy Participants
- Interventions
- Other: Road-tracking testOther: Car-following testOther: Harsh-braking test
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03413592
- Locations
- ๐ฏ๐ต
Taisho Pharmaceutical Co., Ltd selected site, Fukuoka, Japan
Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1
Not Applicable
Completed
- Conditions
- Healthy Participants
- Interventions
- Other: Road-tracking testOther: Car-following testOther: Harsh-braking test
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03278080
- Locations
- ๐ฏ๐ต
Taisho Pharmaceutical Co., Ltd selected site, Fukuoka, Japan
A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with Narcolepsy
Phase 2
Completed
- Conditions
- Narcolepsy
- Interventions
- Drug: TS-091 10mgDrug: PlaceboDrug: TS-091 5mg
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT03267303
- Locations
- ๐ฐ๐ท
Taisho Pharmaceutical Co., Ltd selected site, Seoul and other Korean city, Korea, Republic of
Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia
Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: PF-04802540Drug: Placebo
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2010-03-19
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT00876304
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Glendale, California, United States
A Study Of The Effect Of PF-04802540 On Sleep Measures
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: PF-04802540
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2010-03-19
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 13
- Registration Number
- NCT00772512
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, New York, New York, United States
Multiple Dose Safety Study of PF-04802540 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PF-04802540Drug: Placebo
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2010-03-19
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT00756743
- Locations
- ๐ธ๐ฌ
Pfizer Investigational Site, Singapore, Singapore
ยฉ Copyright 2025. All Rights Reserved by MedPath